gild

Gilead (GILD) Stock: Opportunity of Value Trap?
  • Gilead (GILD) Stock: Opportunity of Value Trap?

Gilead (GILD) Stock: Opportunity or Value Trap?

By |May 6th, 2016|

Gilead Sciences, Inc. (NASDAQ: GILD)

At first glance, Gilead Sciences, the maker of blockbuster Hepatitis C drugs Sovaldi and Harvoni, looks very, very cheap. At a stock price of just under $85 a share, you would only need to pay around 7 times current trailing twelve months earnings for a share of the enterprise. For […]

Gilead Sciences (GILD) A Strong Buy After Today's Declines
  • Gilead Sciences (GILD) A Strong Buy After Today's Declines

Gilead Sciences (GILD) A Strong Buy After Today’s Declines

By |January 4th, 2016|

Gilead Sciences, Inc. (NASDAQ: GILD)

The global market is having an incredibly hard time today as the result of poor data that came out of China. As a result, several great stocks are trading an an incredible discount at the moment. One of those stocks is Gilead Sciences. Today, we’ll talk about the data out […]

Gilead Sciences (GILD) Stock: Yet Another Reason To Invest
  • Gilead Sciences (GILD) Stock: Yet Another Reason To Invest

Gilead Sciences (GILD) Stock: Yet Another Reason To Invest

By |November 9th, 2015|

Gilead Sciences, Inc. (NASDAQ: GILD)
If you follow my writing, here or elsewhere, you know that Gilead Sciences is one of my favorite stocks in the biotech space, and for good reason. Gilead Sciences is arguably the most impressive company in biotechnology. Throughout the years, the company has taken complete control of the HCV market […]

Gilead Sciences (GILD): Why You Should Own This Stock!
  • Gilead Sciences (GILD): Why You Should Own This Stock!

Gilead Sciences (GILD): Why You Should Own This Stock!

By |October 9th, 2015|

Gilead Sciences, Inc. (NASDAQ: GILD)
Gilead Sciences is one of the strongest stocks in the biotechnology space today. However, as with just about every stock in the US marketplace, GILD has been having a rough time over the past 3 months or so. Nonetheless, I’m not concerned. In fact, I believe that the declines we’re […]